Ivacaftor pharmacokinetics and lymphatic transport after enteral administration in rats
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064165%3A_____%2F24%3A10478251" target="_blank" >RIV/00064165:_____/24:10478251 - isvavai.cz</a>
Alternative codes found
RIV/00216208:11110/24:10478251 RIV/00216208:11130/24:10478251 RIV/00216208:11310/24:10478251 RIV/00064203:_____/24:10478251
Result on the web
<a href="https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=17WgQFTdo7" target="_blank" >https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=17WgQFTdo7</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.3389/fphar.2024.1331637" target="_blank" >10.3389/fphar.2024.1331637</a>
Alternative languages
Result language
angličtina
Original language name
Ivacaftor pharmacokinetics and lymphatic transport after enteral administration in rats
Original language description
Background: Ivacaftor is a modern drug used in the treatment of cystic fibrosis. It is highly lipophilic and exhibits a strong positive food effect. These characteristics can be potentially connected to a pronounced lymphatic transport after oral administration. Methods: A series of studies was conducted to describe the basic pharmacokinetic parameters of ivacaftor in jugular vein cannulated rats when dosed in two distinct formulations: an aqueous suspension and an oil solution. Additionally, an anesthetized mesenteric lymph duct cannulated rat model was studied to precisely assess the extent of lymphatic transport. Results: Mean +- SD ivacaftor oral bioavailability was 18.4 +- 3.2% and 16.2 +- 7.8%, respectively, when administered as an aqueous suspension and an oil solution. The relative contribution of the lymphatic transport to the overall bioavailability was 5.91 +- 1.61% and 4.35 +- 1.84%, respectively. Conclusion: Lymphatic transport plays only a minor role in the process of ivacaftor intestinal absorption, and other factors are, therefore, responsible for its pronounced positive food effect.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30104 - Pharmacology and pharmacy
Result continuities
Project
—
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Others
Publication year
2024
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Frontiers in Pharmacology
ISSN
1663-9812
e-ISSN
1663-9812
Volume of the periodical
15
Issue of the periodical within the volume
February
Country of publishing house
CH - SWITZERLAND
Number of pages
8
Pages from-to
1331637
UT code for WoS article
001175811600001
EID of the result in the Scopus database
2-s2.0-85186616289